Retrospective analysis of ovarian cancer patients treated with PARP inhibitors.

• DOI: 10.1200/jco.2021.39.15_suppl.e17555
• Publication Date: 2021-06-02T14:23:28Z
• Authors: Connie Liang; Ashley Leung; Chung-Shien Lee; Jennifer Hernandez; Kit Cheng; Dimitre C. Stefanov; Veena S. John
• Keywords: Olaparib; PARP inhibitor

e17555 Background: Over the last few years, targeted therapy has become mainstay maintenance treatment of patients with ovarian cancer including BRCA1 or BRCA2 mutations. Poly ADP ribose polymerase (PARP) inhibitors are effective in who complete partial remission. PARP known to cause hematological adverse events (AEs), but have not been compared directly each other. Methods: We conducted a single institution, IRB approved, retrospective study on were treated from December 2016 October 2020. Patients stratified according which inhibitor they received. Our primary objective was assess incidence and non-hematological associated use used cancer. Data absolute neutrophil count, hemoglobin platelet count during first 2 cycles graded for hematologic toxicity CTCAE v 5.0. Results: A total 126 received time frame. 34 excluded 92 included analysis. Median age 64.3 (range, 33.8 92.3) 66 (71.7%) white, 84 (91.3%) had an ECOG PS 0/1. Thirty-one (33.7%) niraparib 61 (66.3%) olaparib. group experienced more AEs, 11 (35.5%) (95% CI 19.2-54.6), 20 (64.5%) 45.4-80.8), 18 (58.1%) 39.1-75.5) experiencing neutropenia, anemia, thrombocytopenia, respectively. Eight (13.1%) 5.8-24.2), 24 (39.3%) 27.1-52.7), 16 (26.2%) 15.8-39.1) olaparib Conclusions: This institution outlines toxicities observed between two inhibitors. Although there four approved by FDA, our data only (as most commonly prescribed institution). results suggested that tended be higher risk than showed anemia as common consistent what widely documented literature.